ATE322263T1 - Verbessertes transdermales abgabesystem für die verabreichung von rotigotin - Google Patents

Verbessertes transdermales abgabesystem für die verabreichung von rotigotin

Info

Publication number
ATE322263T1
ATE322263T1 AT03766331T AT03766331T ATE322263T1 AT E322263 T1 ATE322263 T1 AT E322263T1 AT 03766331 T AT03766331 T AT 03766331T AT 03766331 T AT03766331 T AT 03766331T AT E322263 T1 ATE322263 T1 AT E322263T1
Authority
AT
Austria
Prior art keywords
rotigotine
matrix
tds
delivery system
transdermal delivery
Prior art date
Application number
AT03766331T
Other languages
English (en)
Inventor
Mike Hannay
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of ATE322263T1 publication Critical patent/ATE322263T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT03766331T 2002-07-30 2003-07-28 Verbessertes transdermales abgabesystem für die verabreichung von rotigotin ATE322263T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02016860A EP1386605A1 (de) 2002-07-30 2002-07-30 Verbessertes transdermales System für die Verabreichung von Rotigotin

Publications (1)

Publication Number Publication Date
ATE322263T1 true ATE322263T1 (de) 2006-04-15

Family

ID=30011090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766331T ATE322263T1 (de) 2002-07-30 2003-07-28 Verbessertes transdermales abgabesystem für die verabreichung von rotigotin

Country Status (19)

Country Link
EP (2) EP1386605A1 (de)
JP (2) JP4837916B2 (de)
KR (1) KR101016838B1 (de)
CN (2) CN101953819A (de)
AT (1) ATE322263T1 (de)
AU (1) AU2003258539B2 (de)
BR (1) BR0313091A (de)
CA (1) CA2491366A1 (de)
DE (1) DE60304477T2 (de)
DK (1) DK1524975T3 (de)
ES (1) ES2256780T3 (de)
IL (1) IL165918A0 (de)
MX (1) MXPA05000350A (de)
NO (1) NO333297B1 (de)
PL (1) PL217079B1 (de)
PT (1) PT1524975E (de)
SI (1) SI1524975T1 (de)
WO (1) WO2004012730A1 (de)
ZA (1) ZA200500252B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386605A1 (de) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Verbessertes transdermales System für die Verabreichung von Rotigotin
EP1386604A1 (de) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Verbessertes transdermales Verabreichungssystem
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2006039532A2 (en) * 2004-09-29 2006-04-13 Schwarz Pharma, Inc. Transdermal therapeutic system for parkinson’s disease
US7353034B2 (en) 2005-04-04 2008-04-01 X One, Inc. Location sharing and tracking using mobile phones or other wireless devices
CN102281873A (zh) * 2008-10-06 2011-12-14 迈兰技术有限公司 非晶罗替戈汀（rotigotine）透皮系统
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
HUE039447T2 (hu) 2009-12-22 2018-12-28 Ucb Biopharma Sprl Polivinilpirrolidon rotigotin nem kristályos formája szilárd diszperziójának stabilizálására
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
CN103476404B (zh) 2011-03-24 2017-09-29 帝国制药美国公司 包含活性剂层和活性剂转化层的透皮组合物
EP2559435A1 (de) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotin in der Behandlung von Hemineglekt, Schlaganfall und Defiziten nach einem Schlaganfall
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
CA2878376C (en) * 2012-07-05 2018-08-07 Sk Chemicals Co., Ltd. Transdermally absorbable preparation containing rotigotine
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
WO2014198423A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Dreischichtiges transdermales therapiesystem (tts)
ES2694662T3 (es) 2013-07-03 2018-12-26 Lts Lohmann Therapie-Systeme Ag Sistema terapéutico transdérmico con componente electrónico
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
JP6895755B2 (ja) * 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
KR102364378B1 (ko) 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
CN104382850B (zh) * 2014-10-17 2017-12-22 烟台大学 一种罗替戈汀微乳及微乳凝胶
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
PT3854388T (pt) 2020-01-24 2023-12-11 Luye Pharma Switzerland Ag Sistema terapêutico transdérmico com o princípio ativo rotigotina e pelo menos um adesivo de silicone não resistente a aminas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
ES2203563T3 (es) * 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
EP1386604A1 (de) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Verbessertes transdermales Verabreichungssystem
EP1386605A1 (de) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Verbessertes transdermales System für die Verabreichung von Rotigotin

Also Published As

Publication number Publication date
NO333297B1 (no) 2013-04-29
JP2011219485A (ja) 2011-11-04
NO20050472L (no) 2005-01-27
DE60304477D1 (de) 2006-05-18
PL217079B1 (pl) 2014-06-30
ES2256780T3 (es) 2006-07-16
PL374814A1 (en) 2005-10-31
WO2004012730A1 (en) 2004-02-12
EP1524975B1 (de) 2006-04-05
JP5564469B2 (ja) 2014-07-30
CA2491366A1 (en) 2004-02-12
PT1524975E (pt) 2006-07-31
EP1386605A1 (de) 2004-02-04
BR0313091A (pt) 2005-06-21
DK1524975T3 (da) 2006-07-31
AU2003258539A1 (en) 2004-02-23
AU2003258539B2 (en) 2008-08-21
MXPA05000350A (es) 2005-03-31
EP1524975A1 (de) 2005-04-27
EP1524975B9 (de) 2012-02-22
JP2005535687A (ja) 2005-11-24
CN101953819A (zh) 2011-01-26
KR101016838B1 (ko) 2011-02-22
CN1671375A (zh) 2005-09-21
KR20050056942A (ko) 2005-06-16
ZA200500252B (en) 2006-01-25
JP4837916B2 (ja) 2011-12-14
SI1524975T1 (sl) 2006-06-30
IL165918A0 (en) 2006-01-15
DE60304477T2 (de) 2006-12-14

Similar Documents

Publication Publication Date Title
ATE322263T1 (de) Verbessertes transdermales abgabesystem für die verabreichung von rotigotin
HK1083458A1 (en) Improved transdermal delivery system
DK1418894T3 (da) Transdermalt terapeutisk system med fentanyl
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
IE800059L (en) Polymeric diffusion matrix
AU7253501A (en) Transdermal therapeutic system for highly dispersed silicon dioxide
DE60314298D1 (de) Therapeutisches pflaster mit capsaicin-haltiger polysiloxan-matrix
NO923699L (no) Fremgangsmaate og innretning for medisering via hud
RU2009137122A (ru) Устройство для трансдермального введения бисопролола
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
WO2016149077A3 (en) Fentanyl transdermal delivery system
DK1034780T3 (da) Tyndt betametason- og hyaluronsyrebehandlet hæfteplaster til behandling af psoriasis, dermatitis og dermatose
DE50100870D1 (de) Transdermales therapeutisches system zur verabreichung von zaleplon
BRPI0011135B8 (pt) sistema de ministração terapêutica transdérmica contendo agente neuroléptico
DE20221159U1 (de) Transdermales therapeutisches System mit Fentanyl bzw. verwandten Substanzen
ATE485817T1 (de) Pflaster, enthaltend fentanylum

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1524975

Country of ref document: EP

EEIH Change in the person of patent owner